|
This activity is sponsored by the Discovery Institute for
This activity is supported by an educational grant from the
|
 |
INTRODUCTION In accordance with the Discovery Institute of Medical Education policies regarding financial and off-label disclosures, participants are advised that this CME activity may contain references to off-label or unapproved uses of drugs or devices. Participants should note that the use of these agents outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. © 2007–2008 Discovery Institute of Medical Education
Activity Purpose The purpose of this program is to educate clinicians on PAD and its cardiovascular cross-risk. Recent treatment guidelines and clinical trial data will be used to discuss treatment approaches and the benefits of risk factor modification in patients with PAD. Statement of Need Epidemiologic projections suggest that 16% of the European and North American population aged 55 years and older has peripheral arterial disease (PAD). Of the 27 million people with PAD, an estimated 10.5 million are symptomatic, while 16.5 million are asymptomatic. Like patients who have symptoms of PAD, patients who are asymptomatic are at increased risk of atherothrombotic events including stroke, myocardial infarction, internal carotid artery stenosis, and impaired lower-extremity functioning. Cerebrovascular disease, coronary artery disease, and PAD are now clearly thought to be all part of a much larger systemic and interrelated pathologic process known as atherothrombosis, which manifests in atherothrombotic and ischemic events throughout the vasculature. Multiple diagnostic tests, procedures, and therapies are available to treat atherothrombotic disease and accompanying risk factors. Using all available and appropriate diagnostics and therapies to identify and treat every patient is important because of death due to coexisting cardiovascular disease. Recent guidelines, clinical trials, and reviews of available literature warrant further review and may affect how PAD and atherothrombotic disease are managed. Learning Objectives Upon completion of this activity, participants should be able to
Accreditation Statement DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement DIME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Faculty Disclosures DIME requires that those involved with content development and/or presentation disclose to participants any significant financial interest or other relationship (1) with the manufacturers of any commercial products(s) and/or providers(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. This CME activity may include discussions regarding the use of medications that may be outside the approved labeling for these products. Physicians should consult the current prescribing information for these products. DIME requires faculty members to disclose that a product is not labeled for the use under discussion. Compliance is documentation that demonstrates the provider has a requirement in place to make this known to the faculty. William R. Hiatt, MD, FACP Instructions to Participants Course participants must view the slide presentations and complete both a test and a course evaluation to receive continuing medical education credit. No fees are charged to participate in the program or to receive the certificate. Full instructions are available on the user instructions page. Disclaimer The opinions expressed herein are those of the faculty and do not necessarily represent the views of the sponsors, commercial supporters, or publisher. Please review complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients. Medicine is a constantly changing science, and clearly established therapies are not always available for every condition. New research findings necessitate continual changes in drug and treatment therapies. Reasonable efforts have been made to provide up-to-date, accurate information that is within generally accepted medical standards at the time of publication. However, as medical science is ever evolving, and human error is always possible, the provider, commercial supporters, and publisher (or any other involved party) do not guarantee total accuracy or comprehensiveness of the information in this article, and they are not responsible for omissions or errors or the results of using information provided in this course. Participants should confirm the accuracy of the information in this activity from other sources. In particular, all drug doses, indications, and contraindications should be confirmed in package inserts. Click here to view minimum system requirements.
|
